HIV

Men who have sex with men had the highest number of HIV diagnoses.

A look at last week's top stories in the world of pharmacy.

The drug is indicated as a combination treatment of HIV and for pre-exposure prophylaxis.

FDA approves first generic version of emtricitabine and tenofovir disoproxil fumarate (Truvada).

There are few shortcuts that address the large number of medications and different treatment regimens that are needed to treat patients with HIV.

Often, pharmacists look for shortcuts so they can remember complex information or update outdated learning, a technique that most pharmacists learn and refine while they are in pharmacy school. But when it comes to treatment of HIV, there are few shortcuts that address the large number of medications and different treatment regimens that are needed to treat patients.

Treatment de-escalation would reduce adverse events, treatment costs, and the need for virological monitoring.

The findings could lead to speed the development of an HIV vaccine.

Top news of the day from across the health care landscape.

The TZA test is faster, more cost-effective, and less labor-intensive than the current test for finding dormant HIV cells.

Gilead plans to file for approval of novel HIV drug in the United States and Europe this year.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses trends in specialty drug cost management.

HIV-positive individuals are twice as likely to die of smoking than the disease.

Patients with HIV can now expect to live into old age, and therefore need links to the community health network.

Many community pharmacists wonder what they can and should do for their patients who have HIV.

Isentress has been used as a component of treatment regimens for patients diagnosed with HIV-1 for almost a decade.

Isentress HD is a once daily treatment for HIV-1 that helps patients achieve viral suppression.

Cost of once daily version of Isentress will match price for twice daily HIV drug.

Novel strategy prolongs immune system defense against HIV.

Individuals with HIV are at 1.5-2 times the risk of cardiovascular disease and a disproportionate risk of death.

Epoetin alfa biosimilar has indications in cancer, HIV, and chronic kidney disease, among other conditions.

This is the first recommendation for a proposed erythropoiesis-stimulating agent biosimilar.

Scientists project combining prevention programs could avert up to 40,000 HIV infections over 20 years among injection drug users.

Collaboration is part of a citywide plan to ensure patients with HIV receive care and to reduce the number of new HIV transmissions.